Biomedicine & Pharmacotherapy · 2024 · 23 citations · 35 references
Life SciencesImmunologyMicrobiologyDrug DiscoveryMedical MicrobiologyMicrobiome ResearchGut MicrobiomeGut MicrobiotaInflammatory Bowel DiseaseMicrobiome TherapeuticsPrebioticsBacteroides SpeciesGut Microbiota CompositionGut Microbiota EffectsHerbal Drug DiscoveryInflammatory Bowel Disease DysbiosisIntestinal Microbiota ModulationPrebiotic Effects On Gut MicrobiotaPrebiotic Mechanisms
Ulcerative colitis (UC) represents an inflammatory disease characterized by fluctuations in severity, posing substantial challenges in treatment. The gut microbiota plays a pivotal role in the pathogenesis of UC. This study sought to identify drugs specifically targeting the gut microbiota to mitigate UC. We initiated a meta-analysis on gut microbiota in UC patients to identify UC-associated bacterial strains. Subsequently, we screened 164 dietary herbal medicines in vitro to identify potential prebiotics for the UC-associated bacterium, Bacteroides thetaiotaomicron. The DSS-induced colitis mouse model was utilized to evaluate the anti-colitis efficacy of the identified dietary herbal medicine. Full-length 16 S rRNA amplicon sequencing was employed to observe changes in gut microbiota following dietary herbal medicine intervention. The relative abundance of Bacteroides was notably diminished in UC patients compared to their healthy counterparts. B. thetaiotaomicron exhibited an inverse relationship with UC symptoms, indicating its potential as an anti-colitis agent. In vitro assessments revealed that H. Herba significantly bolstered the proliferation of B. thetaiotaomicron. Further experiments showed that treating DSS-induced mice with an aqueous extract of H. Herba considerably alleviated colitis indicators such as weight loss, colon shortening, disease activity score (DAI), and systemic inflammation. Microbial analysis revealed B. thetaiotaomicron as the sole bacterium substantially augmented by H. Herba in vivo. Overall H. Herba emerges as a promising prebiotic for B. thetaiotaomicron, offering significant anti-colitis benefits. Employing a gut microbiota-centric approach proves valuable in the quest for drug discovery.This study provides a new paradigm for drug discovery that targets the gut microbiota to treat UC.
35
Extensive impact of non-antibiotic drugs on human gut bacteria
Lisa Maier, Mihaela Pruteanu, Michael Kuhn et al. · Nature · 2018 · 1.9K citations · Full text
Laura Wrzosek, Sylvie Miquel, Marie-Louise Noordine et al. · BMC Biology · 2013 · 802 citations · Full text
Bacteroidetes Species Are Correlated with Disease Activity in Ulcerative Colitis
Kei Nomura, Dai Ishikawa, Koki Okahara et al. · Journal of Clinical Medicine · 2021 · 155 citations · Full text